NeurologyLive® Friday 5 — August 22, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Key Considerations in the Use of On-Demand Therapy for Parkinson OFF Episodes: Cheryl Kyinn, PA-C

The physician assistant specializing in Parkinson disease talked about how comorbidities and patient preference guide clinical decisions in prescribing on-demand therapies for Parkinson disease. [WATCH TIME: 5 minutes]

2:The Growing Care Impact of Speech and Physical Therapy in Parkinson Disease: Cynthia Fox, PhD, CCC-SLP

The CEO and co-founder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based physical therapies, occupational therapies, and speech therapies. [WATCH TIME: 5 minutes]

3: The Complement Connection in Guillain-Barre and Chronic Inflammatory Demyelinating Polyneuropathy

Explore the role of the complement system in autoimmune neuropathies like GBS and CIDP, and discover innovative therapeutic strategies targeting complement pathways.

4: NeuroVoices: Dennis Rivet, MD, on Expanding the Role of GLP-1 RAs to Idiopathic Intracranial Hypertension and Beyond

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonweath University discussed the rationale, results, and future directions of GLP-1 RA therapy as a novel treatment strategy for idiopathic intracranial hypertension.

5: Overviewing the Role of Amyloid-ß Oligomers and Valiltramiprosate in Alzheimer Disease: John Hey, PhD

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]